Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule…
Six FDA-approved BTK inhibitors now treat both blood cancers and autoimmune diseases, giving doctors expanding options for patients who previously had limited therapies.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Certified Reference Materials for Standardization of cfDNA Isolation…
Standardized reference materials for blood cancer detection tests could make early screening more reliable and consistent across different labs worldwide.
Standard additionRetrospective analysis of clinical outcomes and risk factors in…
Real-world data on transplant outcomes helps doctors make better decisions for lymphoma patients whose cancer returns after newer drug treatments.
Promising but preliminaryPristimerin drives ROS-dependent apoptosis in cutaneous T-cell…
A natural compound shows promise in killing cutaneous lymphoma cells, and combining it with existing drugs suggests a potential new treatment path.
Standard additionIntegrating Multi-Omics and Artificial Intelligence for Personalized…
Artificial intelligence and genetic profiling together are moving closer to personalized breast cancer care, though challenges in translating this to clinics remain.